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ABSTRACT 
Resistance to all known antibiotics is a growing concern worldwide, and has renewed the interest in 
antimicrobial peptides, a structurally diverse class of amphipathic molecules that essentially act on the 
bacterial membrane. Propelled by the antimicrobial potential of this compound class, we have designed 
three new lipopeptides derived from polymyxin B, sp-34, sp-96 and sp-100, with potent antimicrobial activity 
against both Gram positive and Gram negative bacteria. The three peptides bind with high affinity to 
lipopolysaccharide as demonstrated by monolayer penetration and dansyl-displacement. The interaction with 
the cytoplasmic membrane has been elucidated by biophysical experiments with model membranes of 
POPG or POPE/POPG (6:4), mimicking the Gram positive and Gram negative bacterial membrane. Trp-
based fluorescence experiments including steady-state, quenching, anisotropy and FRET, reveal selectivity 
for anionic phospholipids and deep insertion into the membrane. All three lipopeptides induce membrane 
fusion and leakage from anionic vesicles, a process that is favored by the presence of POPE. The molecules 
bind to zwitterionic POPC vesicles, a model of the eukaryotic membrane, but in a different way, with lower 
affinity, less penetration into the bilayer and no fusion or permeabilization of the membrane. Results in model 
membranes are consistent with flow cytometry experiments in Escherichia coli and Staphylococcus aureus 
using a membrane potential sensitive dye (bis-oxonol) and a nucleic acid dye (propidium iodide), suggesting 
that the mechanism of action is based on membrane binding and collapse of membrane integrity by 
depolarization and permeabilization.  
 
1. Introduction 
Disease-causing microbes that have become resistant to antibiotic drug therapy are an increasing public 
health concern [1,2]. Part of the problem is that bacteria are remarkably resilient and have developed several 
ways to resist antibiotics. However, the main reason is our increasing use, and misuse, of existing antibiotics 
in human and veterinary medicine and in agriculture. Unless antibiotic resistance problems are detected as 
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they emerge, and actions are taken immediately to contain them, society could be faced with previously 
treatable diseases that have become again untreatable, as in the pre-antibiotic era.  In particular there is 
substantial concern worldwide with the mounting prevalence of infections caused by multidrug-resistant 
bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and 
certain Gram negative bacteria such as Pseudomonas aeruginosa, Acinetobacter baumanii and Klebsiella 
pneumomiae [3].  Conventional antibiotics typically interact with one or more specific target protein or 
receptor, and genetic resistance appears at a rate that depends on many factors, such as the number of 
targets.  These phenomena have led to intensive efforts aimed at the development of novel drugs targeting 
the bacterial cell membranes, such as antimicrobial peptides (AMP’s). AMP´s offer a new class of 
therapeutic agents to which bacteria may not be able to develop genetic resistance, since they act on the 
lipid component of the cell membranes [4,5]. Among these compounds, polymyxin B (PxB) is acquiring new 
therapeutical relevance and is starting to be considered as a representative of a new class of antibiotics 
against multiresistant bacteria [6,7]. PxB and other members of the polymyxin family such as colistin are 
drugs of last resort to treat Gram negative multiresistant infections [8,9]. In addition, resistance to polymyxins 
is rare, and generally adaptive and thus reversible.  PxB is also capable of inhibiting the biological activities 
of bacterial lipopolysaccharide (LPS) through high-affinity binding to the lipid A moiety, being the agent of 
choice to treat septic shock.  Considering the above, there is no doubt on the importance of developing new 
molecules that maintain or improve the activity of polymyxins and at the same time present lower toxicity.  
The mechanism of action of PxB is not based on a detergent or lytic effect on the membrane, as it was 
previously thought.  Biophysical studies using model membranes have demonstrated that PxB induces the 
apposition of anionic vesicles and the formation of functional vesicle-vesicle contacts that support a fast and 
selective exchange of phospholipids exclusively between the outer monolayers of the vesicles, maintaining 
intact the inner monolayers and the aqueous contents [10,11]. This biophysical phenomena has been 
proposed as the mechanism of antibacterial action of PxB and several other antibiotic peptides [12,13]. 
In this paper we describe new cationic lipopeptides based on the structure of the Gram negative 
selective antimicrobial PxB that show activity against both Gram positive and Gram negative bacteria.  PxB, 
as most basic nonribosomal peptides, is a complex molecule to approach synthetically. We have previously 
described the synthesis and biophysical activity of sp-B [14,15], an analogue that keeps the basic features of 
PxB that are important for activity. Biophysical studies have shown that sp-B interaction with phospholipid 
vesicles is analogous to the interaction of PxB. Both PxB and sp-B bind selectively to anionic membranes 
and induce the formation of vesicle-vesicle contacts and selective lipid exchange. Based on this lipopeptide, 
we have designed a series of more than 100 analogues with different substitutions, and tested their 
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antibacterial activity [16]. From these results, we have selected three lipopeptide analogues, sp-34, sp-96, 
and sp-100 (structures in Table 1), that show broad spectrum activity. The three compounds share a (D)-
tryptophan in position 7, replacing (D)-phenylalanine, thus conferring the molecules intrinsic fluorescence. In 
addition, several key Dab residues are mutated to Arginine. Other modifications include a (D)-cysteine in 
position 10 (sp-96 and sp-100), and Norleucine instead of Leu7 (sp-100).  The influence of the lipid tail is also 
explored by including either C9 or C10 acyl chain in the N-terminus.  The rationale for these modifications is 
summarized in the Discussion section of this work. We have determined the antimicrobial activity on Gram 
positive and Gram negative bacteria, and analyzed the interaction with lipid vesicles with a composition 
strategically designed to simulate the outer leaflet of cell membranes. Our goal was to see which role 
interactions with the lipid matrix of the target membranes play in the biological effects. Unilamelar vesicles of 
POPG or a mixture POPE/POPG (6:4) were used.  In general, higher amounts of PEs are found in Gram 
negative bacteria, whereas Gram positive bacteria are better modeled with PG [17]. LPS vesicles and 
monolayers represent the outer leaflet of the Gram negative outer membrane. Zwitterionic POPC vesicles 
were used to mimic the eukaryotic membrane, as a first approach to detect peptide specificity. We found a 
good correlation between the biophysical studies on model membranes and the antimicrobial activity in vitro. 
The interaction of these molecules with model membranes is consistent with a membrane-based mechanism 
of action, with high specificity for anionic lipids. Destabilization of the bacterial membrane is directly observed 
by flow cytometry in E. coli and S. aureus. 
 
2. Materials and methods 
2.1. Materials   
Polymyxin B sulfate salt (PxB), lipopolysaccharide (LPS) from Salmonella enterica serotype minnesota 
Re 595 (Re mutant), bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC4 (3) or BOX), acrylamide and 
Trizma base (Tris), were purchased from Sigma-Aldrich (St Louis, MO). 1-palmitoyl-2-oleoyl-glycero-sn- 
glycero-3-phospho-(1’-rac-glycerol) (POPG), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine 
(POPE), and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) were from Avanti Polar Lipids 
(Alabaster, Ala).  N-(7-nitro-2-1,3-benzoxadiazol-4-yl) dioleoylphosphatidylethanolamine (NBD-PE), 1-
hexadecanoyl-2-(1-pyrenedecanoyl) glycero-sn-3-phospho-(1’-rac-glycerol)  (pyPG), 1-hexadecanoyl-2-(1-
pyrenedecanoyl) glycero-sn-3-phosphocholine (pyPC), 1-aminonapthalene-3,6,8-trisulfonic acid (ANTS), 
N,N’-p-xylenebis(pyridinium bromide) (DPX), propidium iodide (PI), and dansyl-polymyxin B were purchased 
from Invitrogen Molecular Probes (Eugene, OR). N-fluorenylmethoxycarbonyl (Fmoc)-protected amino acids, 
N,N-diisopropylcarbodiimide (DIPCDI), N-hydroxybenzotriazole (HOBt), trifluoroacetic acid (TFA) as well as 
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nonanoic and decanoic acids were from Bachem and Fluka (Switzerland).  Rink amide resin was purchased 
from Novabiochem (Läufelfingen, Switzerland).  Water was doubly distilled and deionized (Milli-Q system, 
Millipore Corp.). All the lipopeptides were used as water solutions and the concentration was determined by 
quantitative amino acid analysis. 
2.2. Lipid vesicles  
Unilamelar vesicles of POPG, POPE/POPG (6:4) or POPC, alone or with the fluorescently labeled 
phospholipids: pyPG, pyPC or NBD-PE, were prepared by evaporation of a mixture of the lipids and probes 
in CHCl3/CH3OH (2:1 v/v).  The dried film was hydrated for a final lipid concentration of 10 mM, and then 
sonicated in a bath type sonicator (Lab Supplies, Hickesville, NY, Model G112SPIT) until a clear dispersion 
was obtained (2-4 minutes).  For the ANTS/DPX fusion assay, the dried lipid films were dispersed in 12.5 
mM ANTS, 45 mM DPX and 10 mM Tris pH 8.0 and subjected to 10 freeze-thaw cycles prior to extrusion 10 
times through a 0.1 µm polycarbonate membrane at 250 psi N2 pressure (LIPEX, Northern Lipids Inc.). The 
unencapsulated material was separated by gel-filtration on a Sephadex G-50 column eluted with 10 mM Tris 
80 mM NaCl. Osmolarities were adjusted with NaCl and measured in an osmometer (3320 Osmometer, 
Advanced Instruments Inc.). Lipid phosphorus was determined by the Stewart-Marshall assay. These 
vesicles were used within 10 h. Vesicle size was measured by dynamic light scattering with a Malvern II-C 
autosizer, typically obtaining a mean diameter of 80 nm and 105 nm for sonicated and extruded respectively, 
and a narrow size distribution (polydispersity < 0.1). 
2.3. Peptide synthesis and purification 
Peptide synthesis was performed manually following standard Fmoc/tBu procedures using DIPCDI/HOBt 
activation on a Rink amide resin [18].  Once the sequence was assembled, cleavage of the peptides from the 
resin was carried out by acidolysis with TFA:triisopropylsilane:water (95:3:2, v/v) for 90 minutes. TFA was 
removed with N2 stream and the oily residue was treated with dry diethyl ether to obtain the peptide 
precipitate. The solid peptide was isolated by centrifugation. This process was repeated three times. 
Homogeneity of peptide crudes was assessed by analytical HPLC using Nucleosil C18 reverse phase 
columns (4 x 250 mm, 5 μm particle diameter, 120 Å porous). Elution was carried out at 1 ml·min-1 flow with 
mixtures of H2O-0.045% TFA and acetonitrile-0.036% TFA and UV detection at 220 nm. Peptides were 
purified by preparative HPLC on a Waters Delta Prep 3000 system using a Phenomenex C18 (2) column 
(250 x 10 mm, 5 μm) eluted with H2O-acetonitrile-0.1% TFA gradient mixtures and UV detection at 220 nm. 
Cyclization of peptides through disulfide bonds was carried out in 100 mM ammonium bicarbonate aqueous 
solutions with a pH adjusted to 10 by addition of aqueous concentrated ammonia (32%). Final purity was 
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greater than 95%. Peptides were characterized by amino acid analysis with a Beckman 6300 analyzer and 
by MALDI-TOF with a Bruker model Biflex III. 
2.4. Determination of antibacterial activity 
The minimal inhibitory concentrations (MIC) against Escherichia coli (ATTC 25922) and Staphylococcus 
aureus (ATTC 29213) were determined by the broth microdilution method [19] in Mueller-Hinton broth in 96-
well polypropylene microtiter plates with a final concentration of 105 CFU/mL. The MIC was determined as 
the lowest peptide concentration at which growth was completely inhibited after overnight incubation of the 
plates at 37°C.  
2.5. Dansyl-PxB binding and displacement assay.  
The relative binding affinity of each peptide for LPS was determined using the dansyl-polymyxin B 
displacement assay [20], based on the fact that the dansyl group fluoresces when located within a 
hydrophobic lipid environment, whereas it undergoes self-quenching in aqueous solution following 
displacement by membrane-bound species. Fluorescence was measured using a PTI QM4 
spectrofluorimeter with excitation of 340 nm and emission of 485 nm. The saturation of LPS was determined 
by recording the fluorescence after the addition of portions of dansyl-polymyxin to a 1 mL cuvette containing 
3 g/mL of LPS in 10 mM Tris buffer (pH 8.0). The background fluorescence of dansyl-polymyxin was 
determined repeating the same experiment in the absence of LPS. The decrease in fluorescence due to 
dansyl polymyxin B displacement was recorded upon addition of 5 L aliquots of each peptide into a 1 mL 
cuvette containing 3 g/mL of LPS and 2.9 M dansyl-polymyxin (corresponding to 85-90 % of LPS 
saturation). The data was plotted as percent inhibition versus the concentration of peptide (M), and IC50 
values were obtained from these plots. IC50 is defined as the concentration of displacer at which the 
maximum fluorescence intensity of dansyl-polymyxin/LPS saturated complex is reduced to 50% of the initial 
value, and was determined by fitting the fluorescence data to a sigmoidal dose-response model assuming a 
single class of binding sites with GraphPad Prism V5.0 software (GraphPad software, San Diego, CA, USA).  
2.6. Kinetics of insertion into monolayers.  
Monitoring the insertion of peptides into lipid monolayers at constant area, is a sensitive tool for studying 
lipid/peptide interactions [21]. Insertion experiments were conducted at 24°C on a KSV5000 system 
(Helsinki). To avoid carryover of lipid and peptides, the polytetrafluoroethylene (PTFE, Teflon®) trough and 
the Wilhelmy platinum plate were thoroughly cleaned with double-distilled water at >75 °C.  Kinetics of 
insertion at constant area were monitored as an increase in the surface pressure by use of a cylindrical 
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trough (5 cm diameter or 19.6 cm2 area) containing stirred aqueous phase (30 mL) with 10 mM Tris at pH 
8.0. The peptide was added without disturbance of the monolayer via an inlet port in the trough, and the 
surface pressure was continuously recorded. 
2.7. Fluorescence assay for lipid mixing.  
Peptide-induced exchange of lipids between vesicles was assessed as described previously [11]. Briefly, 
transfer of pyrene-labeled phospholipids as donor vesicles (0.83 μM) to an excess of unlabeled phospholipid 
vesicles (106 μM) as acceptors was measured. Emission from vesicles containing 30% pyrene-phospholipid 
is dominated by the excimer band at 480 nm, and the intensity of the monomer band, at 395 nm, increases 
as the probe is diluted due to exchange with excess unlabeled vesicles in contact. Experiments were carried 
out at 24⁰C in 10 mM Tris buffer at pH 8.0 on a PTI QM4 spectrophotometer with constant stirring.  Peptide 
was added from a stock solution 0.25 mM in water to the cuvette containing vesicles of the desired 
composition. Fluorescence emission was monitored at 395 nm (with excitation at 346 nm) corresponding to 
the monomer emission. 
 2.8. Leakage of aqueous contents.  
Dequenching of coencapsulated ANTS and DPX fluorescence resulting from dilution was measured to 
assess leakage of aqueous contents. Fluorescence measurements were performed at 24°C in 10 mM Tris 
buffer at pH 8.0 on a PTI QM4 spectrophotometer with constant stirring by setting the ANTS emission at 530 
nm and the excitation at 350 nm. Peptide was added from a stock solution 0.25 mM in water to the cuvette 
containing vesicles (lipid concentration 115 μM). The 0% leakage corresponded to the fluorescence of the 
vesicle at time zero while 100% leakage was the fluorescence value obtained after addition of Triton X-100 
(10% v/v).  
2.9. Tryptophan fluorescence  
Tryptophan fluorescence spectra were recorded with an excitation wavelength of 285 nm over an 
emission range 300-450 nm, with 4 nm slit widths. Vesicles were added to a 3 M solution of the peptide. 
Titration of the peptide with vesicles was avoided due to the disruption of the vesicles (fusion and leakage) 
that occurs at high peptide-to-lipid ratios. The contribution from scattering due to vesicles was subtracted 
using the same concentration of peptide analogues without tryptophan that induced the same changes in 
light scattering (control experiments, not shown). In some cases, samples were titrated with NaCl to a final 
concentration of 350 mM, to determine the influence of increasing ionic strength.  
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Quenching of tryptophan fluorescence by acrylamide was recorded at 340 nm (excitation 285 nm). 
Appropriate amounts of POPG, POPE/POPG (6:4) or POPC vesicles, were added to a solution of 3 M 
peptide, and aliquots of quencher were added with continuous stirring. Acrylamide was added from a 4 M 
stock solution to a final quencher concentration of 0.3 M.  The Stern-Volmer quenching constants were 








where F0 and F are the fluorescence intensities in the absence and presence of the quencher, [Q] is the 
molar concentration of quencher and V and KSV are the static and dynamic quenching constants.   
Steady-state tryptophan fluorescence anisotropy measurements were carried out at 24 ⁰C in the same 
spectrofluorimeter with L-format polarizers (excitation 285 nm, emission 340 nm). Each measure was done in 
duplicate, independently (no sequential addition of lipid in the same cuvette), adding the vesicles to the 
desired final lipid concentration to a cuvette containing 3 μM lipopeptide. The fluorescence anisotropy (r) was 











where IVv and IVh are the intensities of the emitted polarizer light with the emission polarizer parallel or 
perpendicular to the excitation polarizer. Anisotropy values were automatically corrected for dependencies in 
the detection system (G=IHv/IHh).  
2.10. Fluorescence resonance energy transfer (FRET) to determine peptide binding.  
Binding of lipopeptides to vesicles of different composition containing 2.5% of NBD-PE was determined 
as the increase in the FRET signal from Trp in the peptide to the labeled phospholipid in the interface at 535 
nm (excitation 285 nm). Vesicles (33.3 μM lipid) were titrated with peptide from a stock solution 0.25 mM in 
water, and the relative change in fluorescence (δF) was obtained. δF is defined as (F-F0)/F0, where F0 and F 
are the intensities without and with peptide, respectively. Due to the low lipid concentration used in this 
experiment, the contribution from light scattering is negligible. 
2.11. Flow cytometry 
Bacteria, growth conditions and antimicrobial treatment: An overnight culture (12 to 16 h) of S. 
aureus (ATCC 29213) or E. coli (ATCC 25922) in TSB was grown at 37°C and 400 L were added in 50 mL 
of tryptone water (107 bacteria/mL). The bacterial suspension was split into aliquots of 4-5 mL and treated 
with the peptides (at the MIC) for different contact times at room temperature. Cells were collected by 
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centrifugation (10000 rpm, 20 min) and resuspended in 1 mL of filtered Ringer's solution. Staining procedure: 
A stock solution of PI (1 mg/mL) and BOX (250 µM) was prepared in distilled water. Portions (10 µL and 2 
µL, respectively) were added to aliquots of cells (100 µL of each sample in 1 mL of Ringer's solution) to give 
a final concentration of 10 µg.mL-1 (PI) and 0.5 µM (BOX).  Measurements were performed on a Gallios 
cytometer (Beckman Coulter, CA) set up with the 3-lasers 10 colors standard configuration. Excitation was 
done using a blue (488 nm) laser. Forward scatter (FS), side scatter (SS), green fluorescence (525/40 nm) 
from BOX and red fluorescence (620/30 nm) emitted by PI were collected using logarithmic scales. FS was 
used as the discriminating parameter. The single-cell bacterial population was selected on a forward-side 
scatter scattergram. Fluorescence was presented in a dot plot of BOX vs. PI. Three regions were defined on 
this graph according to the controls: depolarized, permeabilized and non-affected cells. Control cells (non-
stained and single stained populations) were used to define these regions.  25,000 cells defined according to 
their scatter parameters were counted in each sample. 
  
3. Results 
3.1. Antimicrobial activities of the lipopeptides  
Minimal inhibitory concentrations were determined on a Gram negative (Escherichia coli) and a Gram 
positive (Staphylococcus aureus) bacteria. As shown in Table 1, all three lipopeptides were active against 
both types of bacteria, with MIC values in the range from 2.8 to 5.8 μM.  As expected, natural PxB was very 
effective against E. coli, but displayed no antimicrobial activity against S. aureus. 
 
3.2. Peptide binding to LPS  
Antimicrobial peptides with activity against Gram negative bacteria must first bind to LPS in the outer 
membrane in order to reach the target inner membrane, a mechanism know as self-promoted uptake [23]. 
The interaction of the synthetic lipopeptides with LPS from S. minnessota was quantified using the dansyl-
polymyxin displacement assay. Table 2 shows the maximum displacement relative to non dansylated PxB, 
 
Table 1.  Peptide sequences used in this work and antibiotic activity in a Gram negative (Escherichia coli) and a Gram positive 
(Staphylococcus aureus) bacteria. 
 
 Sequence 
MIC  μg.ml-1 (μM) 

















R1, (S)-6-methyloctanoyl ; C9, nonanoyl; C10, decanoyl 
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which is taken as 100%, and the peptide concentration needed for 50% of the maximum displacement. IC50 
for PxB was 3.6 μM, in agreement with previously reported values [24]. The three lipopeptides show a high 
affinity for LPS, with maximum displacement of dansyl-polymyxin comparable to that of PxB. The IC50 are 
even lower than for PxB, with only 2.8 μM in the case of sp-100. 
Lipid monolayers of LPS are a good model to study the interaction of the lipopeptides, since LPS forms 
only the outer layer of the bacterial OM. Insertion of the antibiotic peptides in the LPS monolayer at the 
air/water interface packed at 32 mN.m-1 is monitored as an increase in surface pressure vs. time. Results in 
table 2 correspond to the increases in surface pressure 60 minutes after peptide injection, and clearly sp-34 
is the analogue with a higher degree of insertion, with 9 mN.m-1 of pressure increase, followed by PxB with 5 
mN.m-1. The two analogues with a C10 tail at the N-terminus induced small (around 2 mN.m-1), but 








3.3. Permeabilization of the lipid membrane induced by the lipopeptides  
As shown in Figure 1, the three lipopeptides induced leakage from anionic vesicles, with efficiencies 
depending on liposome composition.  Analogue sp-100 induces permeabilization of POPG liposomes from 
very low peptide/lipid mole ratios (Fig. 1 top). Leakage is very fast upon addition of the peptide, and reaches 
a constant value until a second aliquot is added, thus suggesting that the peptide is irreversibly bound and 
an all-or-nothing type of permeabilization. In contrast, lipopeptides sp-34 and sp-96 do not induce significant 
leakage at peptide/lipid rations below 0.02:1, very similar to PxB behavior. Increasing the peptide 
concentration results in leakage but always lower than for the same concentration of sp-100. All three 
lipopeptides are very effective in inducing leakage from mixed POPE/POPG (6:4) liposomes (Fig. 1 middle), 
with an almost linear increase in permeability at peptide-to-lipid rations above 0.03, which corresponds to 
MIC peptide concentration at the onset of antibacterial activity (3 μM), whereas PxB induces almost no 
leakage at concentrations corresponding to its MIC. Leakage from POPC vesicles is very low in all cases, 
Table 2. Displacement of dansyl-polymyxin bound to LPS from S. 
minnesota by the synthetic analogues  
 
Peptide Imax (%)a IC50b (μM) ∆c  
(mN.m-1) 
PxB 100 3.6 5 
sp-34 97.4 3.3 9 
sp-96 80.9 3.3 2 
sp-100 92.5 2.8 2 
amaximum dansyl-polymyxin displacement compared to PxB, 
taken as 100%; bpeptide concentration required for 50% LPS 
binding; cincrease in surface pressure 60 minutes after injection 
under a monolayer of LPS at 32 mN.m-1.   
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although there is some detectable permeabilizing effect that tends to saturate at low peptide/lipid mole ratio 
(Fig. 1, bottom panel). 
3.4. Lipid mixing between vesicles due to antimicrobial lipopeptides 
As summarized in Figure 2, PxB and the synthetic lipopeptides show selectivity for anionic vesicles, 
inducing fast exchange of pyr-PG in a concentration-dependent manner, whereas none of the peptides 
induced significant lipid mixing from zwitterionic POPC vesicles, even at high peptide concentrations. In good 
agreement with the leakage of contents, the extent of lipid mixing for the same peptide concentration is 
significantly higher in mixed POPE/POPG (6:4) vesicles, a lipid composition that is more representative of 
the Gram negative bacterial membranes, than in POPG vesicles.  Analogue sp-100 is the most effective 



























Figure 2. Membrane lipid-mixing induced by the peptides. 
Increase in fluorescence intensity of pyrene monomer as a 
function of lipopeptide added to vesicles of different 
composition. (□) sp-100, (○) sp-98, (Δ) sp-34 or (●) PxB. 
Vesicles are a mixture of POPG/pyPG, or POPE/pyPG, or 
POPC/pyPC (0.83 μM) and unlabeled vesicles of the same 
composition (106 μM) in 10 mM Tris pH 8.0. Excitation 346 
nm, emission 395 nm. Note the different scales. 
Figure 1.  Peptide induced leakage from liposomes of 
POPG (top), POPE/POPG (6:4) (middle) and POPC 
(bottom). Increasing concentrations of lipopeptide (□) sp-
100, (○) sp-98, (Δ) sp-34 or (●) PxB were added to a 
solution of liposomes (115 μM) co-encapsulating ANTS 
(12.5 mM) and DPX  (45 mM), and leakage was monitored 
as the increase in fluorescence intensity due to ANTS. 
Excitation 350 nm, emission 530 nm. 
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3.5. Spectral signatures of the lipopeptides upon binding to the membrane  
The emission spectra of all three lipopeptides in buffer has a maximum at 350 nm, indicating that the Trp 
residue is highly exposed to the solvent (Fig. 3). The fluorescence signatures are markedly altered upon 
binding to the membrane (Table 3).  The first important observation is that sp-34, sp-96 and sp-100 are able 
to bind not only the anionic vesicles (POPG and POPE/POPG) but the zwitterionic (POPC) too. However, 
there are important differences depending on the lipid composition, thus reflecting different environments for 
Trp [25] (Fig. 3). Binding to anionic vesicles of POPG or POPE/POPG results in a blue shift of 15-16 nm of 
the emission maximum, indicative that the Trp residue is located in a more hydrophobic environment. The 
blue shift is the same for the three lipopeptides and independent of the peptide-to-lipid ratio. In contrast, 
differences are seen in the emission intensity, with an important increase in the case of sp-100 bound to 
POPG, whereas less significant increases are seen on binding of sp-34 and sp-96. The spectral changes for 
the three lipopeptides in the presence of POPC vesicles are summarized in Table 3; in all cases they show a 
gradual blue shift on the emission maximum that depends on the lipid concentration. At very low peptide-to-
lipid ratio (0.005), when all the peptide is bound, there is a blue shift of 13, 12 and 11 nm for sp-34, sp-96 
and sp-100 respectively, accompanied by an increase in the intensity of emission.  Increasing the P/L ratio 
results in smaller blue shift displacements and less significant changes in fluorescence intensity, probably 
due to an equilibrium between free and bound peptide forms, as also suggested by the presence of an 
isosbestic point (Fig. 3, bottom). Increasing the ionic strength by titrating the samples with NaCl (up to 350 
mM) resulted in no backshift of the emission maximum (results not shown), thus indicating that binding was 
not reversible. 
We next determined the changes in anisotropy of tryptophan fluorescence upon binding (Figure 4 and 
Table 3).  Anisotropy values of the free lipopeptides are very low, as expected from a free peptide of this size 
in solution, where Trp residue has a very high rotational freedom. Binding to POPG vesicles results in an 
important increase in anisotropy, a clear indication that tryptophan is in a more restricted region due to 
intercalation of the lipopeptides between the phospholipids. The increase in anisotropy is almost complete at 
a peptide-to-lipid ratio below 0.01, thus suggesting that all the peptide is bound even at low lipid 
concentrations. In the case of mixed POPE/POPG vesicles, results are very similar, with slightly lower values 
of anisotropy compared to pure POPG vesicles. In the case of POPC binding is more gradual, indicating 
lower affinity, although anisotropy values at high lipid concentration, when all the peptide is bound, are in the 
same range than in anionic vesicles, for example for sp-100, r =0.158 (in POPG) and 0.150 (in POPC) at the 














































































Figure 3.  Tryptophan emission spectrum of sp-34 in 10 mM Tris 
(pH 8.0) (solid line) and in the presence of liposomes composed 
of POPG (panel A), POPE/POPG (6:4 molar ratio) (panel B), or 
POPC (panel C). Peptide/lipid molar ratio 0.02 (closed symbols) 
or 0.005 (open symbols). Peptide concentration was 3 μM. 
Excitation 285 nm. 
Figure 4. Fluorescence anisotropy change of antibiotic peptides 
as a function of lipid concentration. (Δ) sp-34, (O) sp-96, (□) sp-
100.Excitation 285 nm, emission 340 nm. Titrations were carried 
out at 25˚C, adding the lipid vesicles to a solution 3 μM of the 
desired peptide in 10 mM Tris pH 8.0. Each point corresponds to 
a separate experiment. 
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Table 3. Tryptophan fluorescence properties of peptides sp-34, sp-96 and sp-100 in the presence of liposomes of POPG, POPE/POPG 












3.6.  Quenching of (D)Trp by acrylamide 
Results described in the previous section indicate that for sp-34, sp-96 and sp-100, (D)Trp7 intercalates 
into the hydrophobic core of the membrane. We next investigated to what extent this residue is exposed to 
the aqueous phase, by using the water-soluble quencher of indole derivatives acrylamide (Table 4). Free 
lipopeptides show very high quenching constants, both dynamic and static, indicating that (D)Trp is highly 
accessible to acrylamide.  KSV and V values for sp-100, sp-96 and sp-34 are very similar, around 12 M-1 and 
3 M-1 respectively.  When the lipopeptides were bound to POPG, quenching became less efficient, for 
example for sp-34 at P/L = 0.005, KSV and V values were 3.439 M-1 and 1.330 M-1, and very similar 
quenching constants were obtained for sp-96 and sp-100. In agreement with anisotropy results (Fig. 4), Trp-
accessibility was independent of the peptide-to-lipid ratio. Results obtained with mixed POPE/POPG are also 
consistent with a high degree of shielding of the Trp residue from the aqueous solvent due to insertion in the 
bilayer, without significant differences with the insertion into POPG vesicles. Finally, for POPC at P/L of 0.02, 
the higher value of the KSV constant, for example 7.545 M-1 for sp-34 and around 10 M-1 for sp-96 and sp-
100, is indicative of a more exposed tryptophan, or more likely to an equilibrium between free and bound 
peptide. Increasing the lipid concentration (P/L 0.005) favors peptide binding, with lower values of the 
collisional quenching constant. 
 λmax (nm) F/Foa Anisotropy (r) 
Conditions sp-34 sp-96 sp-100 sp-34 sp-96 sp-100 sp-34 sp-96 sp-100 
free peptide 
 
350 350 350 
-- 
 
-- -- 0.028 0.033 0.033 
POPG, P/L = 0.02 
 
335 335 336 1.07 1.15 1.64 0.137 0.165 0.126 
POPG, P/L = 0.005 
 
336 336 337 0.89 0.96 1.45 0.170 0.185 0.158 
POPE/POPG,  
P/L = 0.02 
 
336 335 335 1.09 1.19 1.06 0.126 0.126 0.130 
POPE/POPG,  
P/L = 0.005 
 
337 337 336 0.96 1.07 0.96 0.132 0.142 0.128 
POPC, P/L = 0.02 
 
344 343 345 1.06 1.08 1.05 0.114 0.102 0.100 
POPC, P/L = 0.005 
 
337 338 339 1.21 1.23 1.34 0.135 0.200 0.150 
(a) F is the peptide fluorescence intensity in the presence of liposomes at the wavelength of maximum 
emission, and Fo is the fluorescence of the free peptide at 350 nm. 
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Table 4.  Acrylamide quenching constants (M-1) for antibacterial peptides sp-34, sp-96 and sp-100. KSV and V are the dynamic and static 













3.7. Binding of lipopeptides to vesicles determined by FRET 
The different results in Trp emission fluorescence of sp-34, sp-96 and sp-100 bound to POPG vs. POPC 
vesicles can be due to lower peptide binding to the zwitterionic vesicles or to a different form of the bound 
peptide. In order to distinguish these two possibilities, binding of all three lipopeptides to vesicles containing 
NBD-PE was determined. As shown in Figure 5, FRET intensity increases with the amount of peptide added. 
In the anionic POPG vesicles (Fig. 5 top) FRET signal did not saturate even at very high peptide-to-lipid 
ratios, indicating a very efficient binding. The presence of POPE results in higher FRET for the same 
peptide-to-lipid ratio. For example, in sp-34 at P/L=0.05, the relative increase in fluorescence (δF) is 4.96 for 
the POPE containing vesicles and 3.74 for pure POPG vesicles. The synthetic antimicrobial peptides also 
show binding to POPC vesicles, with a small FRET signal that in this system saturates at P/L around 0.02 
(Fig. 5 bottom). When POPG-labeled vesicles were added to a premixed sample containing any of the 
lipopeptides with POPC vesicles, the FRET signal obtained was much lower than the one under the same 
conditions but without POPC (not shown). For example, for sp-100 binding to POPG vesicles (33.3 μM) at 
P/L 0.02, δF is 1.6, but if the POPG vesicles are added to a mixture of POPC (33.3 μM) with sp-100 (0.66 
Conditions  sp-34 sp-96 sp-100 
10 mM Tris pH 8.0 
 
Ksv 12,4 12,46 11,99 
V 2,867 2,878 3,04 
POPG, P/L = 0.02 
 
Ksv 3,317 2,769 3,101 
V 1,396 1,719 1,524 
POPG, P/L = 0.005 
 
Ksv 3,439 3,621 3,298 
V 1,338 1,335 1,477 
POPE/POPG, 
P/L = 0.02 
 
Ksv 3.245 2.486 3.428 
V 1.283 1.483 1.152 
POPE/POPG,  
P/L = 0.005 
 
Ksv 3.673 2.209 3.591 
V 1.073 1.283 1.049 
POPC, P/L = 0.02 
 
Ksv 7,545 10,3 10,02 
V 0,7895 0,8885 0,4384 
POPC, P/L = 0.005 
 
Ksv 3,535 6,939 5,69 
V 1,51 1,113 1,237 
Quenching constants were obtained by fitting of data according to ref. 22, with r2 values 
always above 0,9998. Peptide concentration 3 μM; acrylamide range 0-350 mM.  
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3.8. Effect on the bacterial membrane potential and integrity by flow cytometry 
Peptide sp-100 was chosen for FC analysis due to the results obtained with the biophysical experiments 
where it demonstrated high membrane activity. To assess the affectation of the membrane due to peptide 
interaction two dyes were used, a DNA-labelling dye (PI) and a potential-sensitive dye (BOX). PI is a non-
permeable fluorochrome that intercalates into double-stranded nucleic acid and is excluded by viable cells, 
Figure 5. Change in FRET intensity at 535 nm 
(excitation at 285 nm) resulting from the addition of 
lipopeptides to vesicles containing 2.5% NBD-PE. 




therefore measurement of the loss of viability produced by antimicrobial agents or other compounds is 
possible [26]. BOX accumulates inside the bacterial cell depending on the difference in charge between the 
two sides of the plasma membrane and therefore differences in membrane potential, due to peptide 
interaction, can be measured [27]. As reported in Figure 6, in E. coli cells treated with sp-100 at the MIC of 8 
µg/ml, a gradual uptake of PI can be observed together with a reduction of viability determined by parallel 
cell count, while the cells with dissipation of membrane potential but without permeabilization only reach 20-
30 %. In contrast, in S. aureus sp-100 causes rapid depolarization, as indicated by BOX fluorescence, but 
membrane permeabilization is less significant and appears after depolarization. For example, after 30 
minutes of exposure there is no significant permeabilization; a maximum value of 20% is reached at 60 
minutes and more contact time did not result in a higher PI uptake, while depolarization of the membrane 




















New antimicrobial lipopeptides derived from PxB have a wide spectrum of activity. Polymyxins, including 
PxB and colistin, are increasingly being used as last-line therapy to treat infections caused by multiresistant 
30 60 12




































Figure 6. Effect of sp-100 on the bacterial membrane determined 
by flow citometry.  E. coli or S. aureus cell samples were 
incubated with sp-100 at the MIC of 8 µg/ml at the indicated 
times. Dotted columns show cells stained with PI, corresponding 
to permeabilized membranes, and grey columns are cells stained 
with BOX (but not with PI), therefore cells that are depolarized. 
Viability reduction determined by plate count is plotted as 
symbols. Controls of untreated cells with the same incubation 
times (<5%) are already subtracted.  
 18 
Gram negative bacteria due to their good antimicrobial activity and relatively low prevalence of resistance 
[6,8].  In an effort to discover new antimicrobial lipopeptides with a better therapeutic index, we have 
previously described several analogues based on the structure of natural PxB. The head-compound is sp-B 
[14]. Sp-B maintains the major putative structural requirements for PxB activity: a cycle of 7 amino acids with 
3 positive charges due to L-α,γ-diaminobutyric acid (Dab) and a hydrophobic domain (D)-Phe-Leu, a linear 
tripeptide with 2 positive charges also due to Dab, and a middle length hydrophobic N-terminal chain. In 
addition, sp-B includes a disulfide bridge between two cystein residues to simplify the synthetic process. Sp-
B interaction with phospholipid vesicles is analogous to the interaction of PxB [14,15]. In this paper, we 
describe three new lipopeptides (Table 1) based on the scaffold of sp-B and including different key 
modifications. They are members of a family of more than 100 analogues synthesized and tested so far [16, 
28-30], and share a (D)Trp7, thus conferring the molecules an intrinsic fluorescence that is very useful to 
characterize membrane binding. The analogues also contain residues of arginine in positions 1-8 (sp-34), 3-
8 (sp-96) and 1-3-8 (sp-100), substituting residues of the non-natural aminoacid Dab. Both Trp and Arg 
residues are known to possess crucial chemical properties that make them suitable components of 
antimicrobial peptides [31,32]. Tryptophan favors the interaction with the interfacial region of the lipid 
membrane, whereas arginine, apart from the cationic charge that is necessary for electrostatic binding to the 
anionic bacterial phospholipids, has better hydrogen bonding properties than Dab or Lys. Arg can form 
cation-π interactions that make the entry into the hydrophobic core of the bilayer energetically more 
favorable. Since most AMPs achieve their bactericidal effect with an initial interaction with the outer and/or 
inner membranes of bacteria, which often is also the site of action, electrostatic and hydrophobic interactions 
with the lipid components are pivotal for activity. For example, in the antimicrobial peptide protegrin-1, with 
two Arg, it has been suggested that guanidinium-phosphate complexation, which neutralizes the guanidinium 
ions before they are inserted into the membrane, results in toroidal-pore formation [33].  In addition, in sp-96 
and sp-100, the C-terminal Cys residue is mutated to a (D)Cys, to better mimic the conformation of the 
natural residue of Thr10 in PxB. Finally, a key mutation is the introduction of NLeu instead of Leu in position 7 
in sp-100, to increase flexibility in this strategic hydrophobic residue. Lipopeptides sp-34, sp-96 and sp-100 
have good antimicrobial activities against E. coli and S. aureus, in contrast with the selectivity for Gram 
negative bacteria that characterizes PxB. We have recently reported the in vitro cytotoxicity of PxB-analogs 
of the same family, containing two or three residues of Arg but without Trp [16]. Results obtained on different 
cell cultures of mammalian cells indicated low toxicity, with IC50 values always above 450 µg.ml-1. 
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Gram negative bacteria have an outer membrane composed mainly of LPS, and LPS binding is a 
necessary first step for antimicrobial action. Antibiotic peptides must enter the periplasmic space by self 
promoted uptake, displacing divalent cations that keep the LPS molecules densely packed, before they 
reach the inner membrane which is generally considered to be the primary target, or other intracellular 
targets [23].  We have shown that sp-34, sp-96 and sp-100 have a high affinity for LPS, comparable to that of 
native PxB, displacing previously bound dansyl-polymyxin from LPS.  All lipopeptides insert into LPS 
monolayers at 32 mN.m-1, a lateral pressure that is in the order of the biological membrane [34]. The longer 
N-terminal acyl chain of sp-96 and sp-100 results in lower increases in surface pressure, probably because 
the peptidic moiety of the bound lipopeptide can accommodate at the interfacial region of LPS. The 
interaction between polymyxins and the lipid A part of LPS has been well characterized at the molecular 
level by NMR and molecular modeling techniques [8,35,36]. The backbone of PxB is folded in an envelope-
like fold, separating the polar residues from the hydrophobic components, thus conferring the structure an 
amphipathic character. The hydrophobic residues (D)Phe6 and Leu7, as well as the N-terminal acyl chain, 
penetrate into the hydrocarbon portion of LPS, whereas the polar residues are oriented to point into the 
hydrophilic environment of the OM. The complex is stabilized by electrostatic interactions between the 
positive charges of the Dab side chains and the phosphates in lipid A. Results obtained with the synthetic 
peptides point towards a similar interaction with LPS, and we can conclude that they will also destabilize the 
OM. 
Fluorescence spectroscopy shows differential binding to POPG, POPE/POPG and POPC model 
membranes. We next studied the interaction of the lipopeptides with liposomes that mimic the cytoplasmic 
membrane of bacteria. Liposomes of pure POPG and mixed POPE/POPG (6:4 mol/mol), were chosen as 
models, based on the reported membrane composition of different bacterial types [17]. In general, 
cytoplasmic membranes of Gram positive bacteria are mostly composed of anionic lipids, whereas high 
contents of PEs are found in Gram negative bacteria. Vesicles of zwitterionic POPC were also prepared as 
models of the eukaryotic membrane.  FRET experiments show that antimicrobial lipopeptides sp-34, sp-96 
and sp-100 bind with high affinity to anionic vesicles of POPG and POPE/POPG (6:4), with a linear 
dependence between FRET intensity and peptide concentration. The higher increase in NBD fluorescence 
observed in POPE/POPG vesicles indicates that the presence of the zwitterionic POPE favors peptide 
binding. Although it is generally accepted that cationic antimicrobial peptides interact with bacterial 
membranes mainly through electrostatic interactions with the anionic phospholipid head groups [37-39], 
FRET results shown here demonstrate that zwitterionic POPE also plays an important role.  Tryptophan 
fluorescence emission spectra, anisotropy measurements and quenching experiments were conducted to 
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characterize the membrane bound form of the three lipopeptides. All three showed comparable fluorescence 
characteristics in buffer, with the fluorescence maxima centered at 350 nm, indicative of Trp residues located 
in a hydrophilic environment [40]. In addition, similar emission intensities reveal a similar environment for 
tryptophan. The very low Trp-anisotropy values and high Trp-quenching constants are consistent with the 
absence of a folded structure in solution. In the presence of the anionic membranes, modifications in Trp 
fluorescence properties are a clear indication of binding and insertion into a more hydrophobic environment. 
The observed blue-shift of around 15 nm, and the significant increases in anisotropy are relatively 
independent on lipid concentration, and indicate that Trp is in a more hydrophobic region of the bilayer, 
where it remains relatively immobilized. Acrylamide quenching is consistent with low accessibility to the 
aqueous phase.  We can conclude that sp-34, sp-96 and sp-100 bind more efficiently to POPE-containing 
POPG vesicles than to pure POPG vesicles, but the three peptides bind in similar forms with equivalent 
spectroscopic properties. Binding to POPC vesicles is significantly less efficient, with a lower intensity in the 
FRET signal that saturates at peptide-to-lipid ratios above 0.02. Spectral signatures in POPC vesicles are 
consistent with a more gradual, concentration-dependent insertion of the lipopeptide. The absence of salt 
effect is indicative of an irreversible binding to the membrane, consistent with the deep insertion of the three 
lipopeptides. Similar results were obtained for the pore-forming cyclic antimicrobial peptide BPC194 on 
binding to anionic membranes [41]. 
Peptide-induced perturbation of the membrane requires the presence of anionic lipids.  Leakage 
experiments show that the three lipopeptides are able to permeabilize vesicles of POPE/POPG in a 
concentration-dependent manner. Sp-100 is the more lytic lipopeptide in this model system, and shows a 
biphasic pattern, with higher membrane-permeabilizing effect above P/L = 0.03, which corresponds to 4 μM 
peptide (the MIC for this lipopeptide against E. coli is 5.5 μM). This elevated peptide-to-lipid ratio suggests 
that possibly sp-100 acts by the “carpet” mechanism, where a minimum amount of bound peptide is needed 
before channels are formed [42].  Lipopeptides sp-34 and sp-96 are only slightly less permeabilizing at the 
same P/L ratio. In contrast, natural PxB has no permeabilizing effect at concentrations corresponding to its 
MIC for E. coli. All three synthetic lipopeptides induce mixing of phospholipids between vesicles of 
POPE/POPG. The efficacy of causing lipid mixing follows the same trend as the ability to induce leakage, 
with sp-100 being the most active peptide. Therefore, sp-100, sp-34 and sp-96 cause leaky fusion of 
POPE/POPG vesicles at concentrations relevant to their antimicrobial activity in E. coli, thus suggesting a 
mechanism of action based on the permeabilization of the cytoplasmic membrane. The possibility of an 
unspecific detergent effect with formation of micelles can be ruled out as demonstrated by a peptide 
concentration-dependent increase in light scattering of the anionic vesicles, indicative of an increase in 
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particle size by clustering of the vesicles (results not shown), as is also the case with PxB and sp-B [14], and 
with sp-85, an analogue of PxB that shows broad spectrum of activity [43]. Interaction of sp-85 with lipid 
monolayers at the membrane equivalence pressure results in an alteration on lipid packing that is consistent 
with membrane fusion and leakage induced upon binding to liposomes of the same composition, and further 
confirmed by TEM images of treated bacteria, with significant modifications on the bacterial cell membrane.  
This behavior is common to other antimicrobial peptides, such as MSI-78 and LL-37 [44,45], and can be 
related to the negative spontaneous curvature imparted by POPE, due to the fact that the polar headgroup 
has a smaller diameter than the hydrocarbon chain region in the fluid phase, and the increased acyl chain 
packing induced by this lipid [46,47]. Many AMPs are known to induce clustering of anionic lipids, causing 
lipid segregation and, as a result, leakage of aqueous contents and/or membrane depolarization [5,47]. The 
biological significance of membrane fusion is poorly understood, however it is likely that the process enables 
the translocation of the peptide molecules across the membrane bilayer [48]. In contrast, results with PxB 
are consistent with a different mechanism of action based on the mixing of lipids between the outer and inner 
membranes and the resulting osmotic imbalance [12,49]. In POPG vesicles differences among the 
lipopeptides are more important, with a weaker effect of sp-34 and sp-96 on the permeability of the 
membrane compared to a fast leakage of aqueous contents induced by sp-100. Also, the efficacy of causing 
lipid mixing follows the same trend as the ability to induce leakage. The effects of sp-34 and sp-96 in this 
system are closer to PxB than to sp-100, which is surprising considering the different MIC values (>102 μM 
for PxB and 5.8 μM for the analogues). There are other examples of antimicrobial peptides that cause no 
significant leakage or fusion in model membranes at concentrations corresponding to their MIC and above. 
In fact, although the mode of action of many AMPs involves disruption of the bacterial membrane integrity, 
other antimicrobial mechanisms have recently been characterized that target key cellular processes such as 
DNA and protein synthesis, protein folding, enzymatic activity and cell wall synthesis [5]. Some AMPs can 
even have several targets, a multi-hit strategy that increases their efficiency reducing the possibility of 
resistance [50]. For example, the Ca+2-dependent antibiotic lipopeptide MX-2401, an analogue of 
amphomycin, inhibits peptidoglycan synthesis by binding to the substrate undecaprenylphosphate, without 
affecting membrane integrity [51]. It is also possible that sp-34 and sp-96 kill the bacteria by inducing non-
lytic depolarization, thus dissipating the membrane potential without further damage. This mechanism has 
been described for daptomycin [51], lactoferricin [52] and certain ceragenins [53].  Even though the synthetic 
lipopeptides bind to zwitterionic POPC membranes, they do not induce significant leakage or fusion, thus 
suggesting that they may not be toxic in eukaryotic cells. These results also emphasize the importance of 
choosing the membrane composition to obtain relevant results: although cationic peptide antimicrobial 
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peptides interact with bacterial membranes mainly through electrostatic interactions with the POPG head 
groups, this cannot be the only governing factor, because the nature of the additional lipid components also 
play a role, as demonstrated with aurein 2.2 and derivatives [54] and plantaricin A [55]. 
Flow cytometry results are consistent with a membrane-based mechanism of action for sp-100 in both E. 
coli and S. aureus. Time-response assays show that in S. aureus collapse of membrane potential occurs 
before collapse of membrane integrity, whereas in E. coli depolarization and permeabilization take place 
roughly at the same time, and PI fluorescence increases with the time of incubation. Viability reduction 
obtained by plate count is generally in good correlation with membrane damage caused by the peptide. For 
example, in S. aureus after 60 minutes of incubation with sp-100, 22% of cells are permeabilized (PI-
stained), and 32% are only depolarized (BOX-stained), therefore a total of 54% of cells are damaged, which 
is consistent with the observed 58% of cell death. FC data is in good agreement with the biophysical 
experiments in model membranes, with more permeabilization from E. coli than from S. aureus, 




We report three new synthetic antimicrobial lipopeptides with Gram positive and Gram negative activity 
derived from the structure of the Gram negative selective antibiotic PxB. Biophysical studies with model 
membranes show that the peptides bind to zwitterionic and anionic membranes, but they require the 
presence of anionic lipids to disrupt the membrane. The inclusion of Arg residues instead of natural Dab 
favors the insertion in the bacterial lipid membrane and allows passage of the peptides across the bilayer. 
The presence of (D)Trp favors membrane interaction and confers the molecule intrinsic fluorescence 
properties that allow the determination of membrane binding. The substitution of Leu by the more flexible 
NLeu increases the permeabilizing and fusogenic capacity. The new lipopeptides described here are good 
candidates to become new antimicrobials, although further work needs to be done to ascertain their 
molecular mechanism of action. 
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